View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 3, 2018

Bioniz reports positive results from Phase Ib trial of BNZ-1

Bioniz Therapeutics has reported positive top-line results from a Phase Ib clinical trial of BNZ-1 to treat Alopecia Areata (AA), a common, inflammatory, immune-mediated hair loss that leads to partial or complete loss of hair on the scalp and body.

Bioniz Therapeutics has reported positive top-line results from a Phase Ib clinical trial of BNZ-1 to treat Alopecia Areata (AA), a common, inflammatory, immune-mediated hair loss that leads to partial or complete loss of hair on the scalp and body.

The randomised, placebo-controlled trial was designed to analyse the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of various multiple doses of intravenous BNZ-1.

During the trial, BNZ-1 was administered to healthy adult subjects.

The trial evaluated three weekly dose cohorts and two alternate weekly dose cohorts in a dose-escalation manner.

“These results establish initial clinical validation of BNZ-1’s potential to treat a variety of IL-2/9/15 cytokine-driven conditions with a novel mechanism.”

It did not find any serious or severe adverse events (AEs), infusion-related reactions, or dose limiting laboratory toxicities.

According to Bioniz, the rate of adverse events reported in the trial was comparable between the pooled BNZ-1 and pooled placebo groups.

Sore throat and runny nose were found to be the only two common adverse events that happened more frequently in the overall BNZ-1 group, compared to the pooled placebo group.

Among other findings, the trial did not observe any dose / exposure-related adverse events.

Bioniz Therapeutics chief medical officer Paul Frohna said: “This Phase Ib study further characterises BNZ-1’s encouraging safety and tolerability profile while producing sustained, dose-dependent, and highly IL-2 / 15-specific pharmacodynamic effects with multiple dosing.

“These results establish initial clinical validation of BNZ-1’s potential to treat a variety of IL-2/9/15 cytokine-driven conditions with a novel mechanism.”

In addition, Bioniz has dosed a total of 53 healthy adult volunteers with BNZ-1 across two Phase I trials. So far, the trials have not observed any dose-limiting side effects, infusion reactions, or serious / severe adverse events.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU